**February 20, 2018**
14-16 February 2018 InSysBio held Annual Internal Scientific Meeting.
Results of the last year have been discussed and summarized. In 2017 we collaborated with seven international pharmaceutical companies in framework of eight projects. Seven pharmaceutical companies began to use Immune Response Template 1.0, a platform for QSP modeling in immunology and immuno-oncology developed by InSysBio. Three research papers have been published in CPT: Pharmacometrics & Systems Pharmacology and Journal of Controlled Release.
We have discussed the progress in ongoing projects such as QSP model of Alzheimer’s Disease (including amyloid beta and tau description), modeling of T cells and CAR-T therapy in oncology, development of QSP modeling software and other projects. This Annual Internal Scientific Meeting was the 11th held by InSysBio.
| ← | October 2025 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
1.
02 Oct 2025 13:23
InSysBio to announce participation in BioTechX Europe 2025 with focus on AI and QSP
InSysBio announces their participation in BioTechX Europe 2025. Oleg Demin, Chief Scientific Advisor and co-founder of InSysBio, and Igor Goryanin, Professor at University of Edinburgh, will host a roundtable discussion entitled, "Integrating Artificial Intelligence with Quantitative Systems Pharmacology (QSP): Opportunities and Challenges"
|
3
|
4
|
5
| ||
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
|
13
|
14
|
15
|
16
1.
16 Oct 2025 12:13
InSysBio to introduce a new data annotation service available in CYTOCON DB and fIVE DB
InSysBio launches a new data annotation service designed to support researchers and analysts who require specific, literature-based biological data to be added to InSysBio’s CYTOCON or fIVE databases for use in QSP modeling, analysis, or decision-making. The new service allows clients to submit targeted data requests related to diseases, tissues, cell types, and cytokines
|
17
|
18
|
19
|
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
|
27
|
28
|
29
|
30
|
31
| ||
Thank you for your message! We will get back to you shortly.
